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Background: Although technical success of renal artery stenting (RAS) is high and adverse events are infrequent, clinical
success (improved blood pressure and renal function) and durability have been less predictable. Identifying those patients
who will respond to RAS could improve overall outcomes of the procedure.
Methods: This was a retrospective analysis of all patients who underwent RAS for treatment of renovascular hypertension
(RVH) between 2001 and 2007 at Dartmouth-HitchcockMedical Center. The primary outcomemeasure was blood pressure
improvement or cure as judged by American Heart Association criteria. Estimated glomerular filtration rate (eGFR), number
of antihypertensivemedications, and survival were evaluated as secondary outcomes.Univariate andmultivariate analyses were
performed to identify factors associated with blood pressure improvement at the last follow-up.
Results: During the 6-year period, 129 patients (179 renal arteries) underwent stent placement for RVH. Procedural
complications occurred nine patients (7.0%). Average length follow-up was 1.5 years. Follow-up data were obtained in
122 patients (95%). At last follow-up, there were significant improvements in systolic blood pressure (161 vs 144mmHg,
P< .001), diastolic blood pressure (80 vs 73mmHg, P< .001), and number of antihypertensive medications (3.1 vs 2.8,
P  .034). The eGFR was improved in 16% of patients, stable in 60%, and worse in 24%. By multivariate analysis, a
baseline eGFR <40 mL/min/1.73 m2 (odds ratio, 1.6; 95% confidence interval [CI], 1.0-2.9; P  .02) and female
gender (OR, 1.3; 95% CI, 1.0-2.1; P  .04) were independent predictors of failure to achieve blood pressure
improvement. By 2 and 4 years of follow-up, sustained blood pressure improvement was present in 67% of patients
with a baseline eGFR of>40 mL/min/1.73 m2 and in 31% of patients with a baseline eGFR<40 mL/min/1.73 m2.
During 2 years of follow-up, survival was similar between patients with sustained blood pressure response and those
without.
Conclusion: Patients treated for RVHwho have a baseline eGFR of>40mL/min/1.73 m2 demonstrate a better response
to RAS at each follow-up interval, with a significant difference at 2 to 4 years, compared with patients with an eGFR<40
mL/min/1.73 m2. (J Vasc Surg 2010;51:380-5.)Percutaneous treatment of atherosclerotic renal artery
stenosis has become increasingly prevalent despite the lack
of good clinical evidence of lasting patient benefit.1 Despite
high technical success and relatively low complication rates,
sustained blood pressure control and improved renal func-
tion have not been uniformly achieved.2-7 However, previ-
ous studies suggest that some patients respond well to renal
artery stent (RAS) placement, at least in the short-term,
whereas others do not.6-11
The group of patients that will benefit most from
therapy has not been identified. Because of the pervasive
use of stents in the renal artery and the concern that some
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380patients are undergoing treatment without a demonstrable
clinical benefit, reimbursement for these procedures has
been questioned by the Centers forMedicare andMedicaid
Services (CMS).12 The AmericanHeart Association (AHA)
published a report in 2005 providing the best clinical
evidence supporting RAS and outlining its recommenda-
tions for therapy.1 The report concludes that there is no
level I evidence demonstrating the efficacy of RAS. More
recently, in comment to CMS in 2007, the AHA expressed
its desire to further delineate those patients that might
benefit most from RAS, stating that “without additional
trials examining PTA and stenting and comparing the
procedure to surgical revascularization and medical man-
agement, it will be difficult to correctly identify the
appropriate patient population for this treatment op-
tion.”
Although most practitioners believe there are patients
who respond to RAS, it is equally clear that some patients
do not. It is critical to identify those patients who will
benefit most from a percutaneous renal intervention. Re-
fined patient selection for RAS will potentially improve
outcomes and decrease the rate of unnecessary interven-
tions and the overall cost to society. The purpose of this
study was to identify preprocedural predictors of failure of
therapy after stent placement in patients with renovascular
hypertension (RVH).
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The Institutional Review Board at Dartmouth Medical
School reviewed and approved our study protocol.
Sample. We used data collected prospectively on all
patients undergoing RAS by 12 vascular surgeons at
Dartmouth-Hitchcock Medical Center from2001 to 2007.
All patients who underwent RAS for refractory RVH, with or
without associated chronic renal insufficiency, were in-
cluded in the database. Four clinicians entered data pro-
spectively on clinical, demographic, procedural, and fol-
low-up variables. Interventions were performed in those
patients with noninvasive imaging suggestive of renal artery
stenosis in whom optimal medical therapy for hypertension
had failed. There were no specific guidelines for exclusion
from intervention. General considerations included evi-
dence of a nonviable or minimally functioning kidney on
the preprocedural work-up or an elevated renal parenchy-
mal resistive index 0.8. No patient in this database was
treated for asymptomatic renal artery stenosis, and patients
with purely ischemic nephropathy without concomitant
hypertension were excluded.
Definitions. Most patients were evaluated with renal
artery duplex ultrasound (DU) imaging using internally
validated Dartmouth-Hitchcock vascular laboratory crite-
ria for clinically significant (60%) stenosis: a ratio of peak
renal artery velocity/peak aortic velocity (renal/aortic ra-
tio) 3.5 or a peak systolic velocity 200 cm/s.
RVH and the clinical responses after RAS were defined
in accordance with the AHA guidelines as listed here.
Indications for intervention included a systolic blood pres-
sure (SBP) 140 mm Hg or diastolic blood pressure
(DBP) 90 mm Hg, or both, which was either refractory
to treatment with three or more antihypertensive medica-
tions (including a diuretic) or was associated with medica-
tion intolerance or acute end organ dysfunction (eg, con-
gestive heart failure).13
Patients were reported as cured if they were no longer
taking any antihypertensive medications and were found in
follow-up to have a SBP 140 mm Hg and a DBP 90
mmHg. Improved hypertension was defined as the patient
taking the same or a reduced number/dose of antihyper-
tensive medications and having a SBP140 mm Hg and a
DBP90 mmHg or the same amount of medication with
a decrease in DBP decrease 15 mm Hg. A failure of
therapy at last follow-up was defined as a failure to meet the
criteria for improved or cured blood pressure.
Renal dysfunction was defined as an estimated glomer-
ular filtration rate (eGFR) 60 mL/min/1.73 m2 as de-
termined by the Modification of Diet in Renal Disease
Study Equation (MDRD). Worsened renal function was
defined as a decrease of at least 20% under the preproce-
dural eGFR level, and improvement as an increase of at least
20% over the preprocedural level. The blood pressure and
renal function responses were determined independently
by a review of the database by four separate evaluators.
Differences in how the evaluators classified the response
were rare and were reconciled through direct discussion.Procedure and follow-up. Procedural specifics from
our institution have been previously published.6 Briefly,
access was obtained through the common femoral or left
brachial artery. Selective renal artery digital subtraction
angiography was used to estimate the degree of stenosis.
Stenosis 60% or a pressure gradient 15 mm Hg, or
both, was considered an indication for intervention. Low-
profile 0.014- or 0.018-inch systems were used. Embolic
protection devices, including the Guardwire (Medtronic,
Minneapolis, MN) and Spider (ev3 Endovascular Inc, Ply-
mouth, Minn), were selectively used in patients with a
baseline creatinine level 2.0 mg/dL or in patients with a
solitary kidney.
All arteries were treated preferentially with balloon-
expandable stents. Stent diameters were6mm in 52% and
6 mm in 48%, and stent size selection was based on the
adjacent normal vessel diameter size. Technical success was
defined as successful stent placement with a residual steno-
sis 30% or a pressure gradient 15 mm Hg, or both. A
residual stenosis (30%) or a pressure gradient (15 mm
Hg) was treated with repeat angioplasty or a second stent if
further coverage of the lesion was indicated. Patients with a
creatinine level1.3 mg/dL underwent pretreatment with
N-acetylcysteine (600 mg orally twice daily on the day
before the procedure and for 48 hours after the procedure)
along with periprocedural bicarbonate (150 mL bicarbon-
ate in 850 mL of D5W at 3 mL/kg for 1 hour and then 1
mL/kg until 5 hours after completion of the procedure).14
Patients had postprocedural follow-up at 1,6, and 12
months and then yearly. Follow-up was more frequent if
clinically indicated. Follow-up included measurements of
bilateral blood pressure and serum creatinine level, and a
surveillance renal artery DU scan.
Data analysis. Patient blood pressure response to
therapy was determined at each completed follow-up inter-
val including all elements of follow-up (blood pressure,
eGFR, and medication regimen). Dichotomous variables
are presented as proportions and compared with the 2 test.
Continuous variables are presented as mean  standard
deviation and compared with t test. Factors associated with
blood pressure improvement were determined using uni-
variate analysis with the Fisher exact test. Univariate pre-
dictors significant with P  .1 were used to perform mul-
tivariate logistic regression. Patient survival was determined
using Kaplan-Meier life-table methods. Comparisons were
made using the log-rank test. All analyses were performed
using Excel (Microsoft, Redmond, Wash) and STATA
software (StataCorp, College Station, Tex).
RESULTS
Patient characteristics. During the 7-year period,
129 patients (53% men) and 179 renal arteries underwent
stent placement, and 439 patient clinic visits with follow-up
data were available for analysis. Mean age of the patients
was 68  10.5 years, 84% were current or former smokers,
and 47% had chronic renal insufficiency (eGFR 60 mL/
min/1.73m2). Other medical comorbidities are detailed in
Table I. Before stent placement, 81% underwent renal
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vessels was 307  134 cm/s and the aortic/renal velocity
ratio was 4.5  2.3.
Procedural and stent characteristics. Femoral access
was used in 88% of patients, and open or percutaneous
brachial artery access was used in 12%. Technical success
was 98% overall. Nine patients (7.0%) sustained periproce-
dural complications, including postprocedural acute renal
insufficiency in 3, stent migration in 1, renal artery dissec-
tion in 5, acute thrombosis in 3, and renal hemorrhage in 2.
Embolic protection devices were used 35 arteries (20%).
Bilateral renal stents were placed in 39 patients (30%), of
which nine were performed in a staged fashion. In 11
arteries (0.6%), two stents were placed in a single vessel.
Mean fluoroscopy time was 32  19 minutes. Mean con-
trast dose was 85  50 mL.
Complete follow-up data, including a renal artery DU
scan, were available for 95% of stented arteries. By life-table
analysis, the 2-year freedom from restenosis, as determined
by surveillance DU, was 52%. Reintervention was required
in 23 vessels (28% of restenosed vessels) because of con-
comitant clinical deterioration.
Blood pressure. Mean follow-up was 544 days (me-
dian, 479 days). Across the sample, mean SBP (161 31 to
144  23 mm Hg; P  .001), DBP (80  15 to 73  10
mm Hg; P  .001), and number of blood pressure medi-
cations (3.1 to 2.8; P  .034) were decreased at last
follow-up (Table II). By AHA criteria, blood pressure was
improved in 51%, 53%, and 59% of patients at 1, 2, and 4
years, respectively (Fig 1). No patients were cured after
RAS.
A baseline eGFR 40 mL/min/1.73 m2 (P  .008),
Table I. Patient demographics
Variable No. %
Male 69 53
Bilateral disease 39 30
Diabetes mellitus 33 26
Coronary artery disease 67 52
Hypercholesterolemia 91 70
Chronic obstructive pulmonary disease 16 12
Smoking 104 84
Abdominal aortic aneurysm 38 29
Chronic renal insufficiency 60 47
Table II. Clinical outcomes
Variable Preprocedure
At last
follow-upa P
SBP, mm Hg 161  31 144  23 .001
DBP, mm Hg 80  15 73  10 .001
Antihypertensives, No. 3.1  1.2 2.8  1.1 .034
eGFR, mL/min/1.73 m2 46  14 44  16 .83
DBP, Diastolic blood pressure; eGFR, estimated glomerular filtration rate;
SBP, systolic blood pressure.
aMean follow-up, 544 days.female gender (P .05), and age70 years (P .10) wereassociated with poor blood pressure response after RAS by
univariate analysis (Table III). By multivariate analysis, a
baseline eGFR 40 mL/min/1.73 m2 (OR, 1.6; 95% CI,
1.0-2.9; P  .02) and female gender (OR, 1.3; 95% CI,
1.0-2.1; P  .04) were associated with failure to achieve
blood improvement after RAS.
The effect of baseline renal function on blood pressure
improvement was further demonstrated by stratifying pa-
tients based on preoperative renal function (eGFR 40 vs
eGFR 40). At each follow-up interval up to 4 years,
patients with an eGFR of 40 mL/min/1.73 m2 had a
better blood pressure response, with a significant difference
(P .02) at 24 to 48 months of follow-up (Fig 2). Survival
in patients who had blood pressure improvement was not
different at 4 years from those who did not achieve BP
improvement (Fig 3).
Renal function. No significant change was noted in
Fig 1. Blood pressure improvement or cure after renal artery
stenting is shown at each follow-up interval.
Table III. Univariate predictors of blood pressure
improvement or cure
Variable P
Abnormal baseline eGFR,a 40 mL/min/1.73 m2 .008
Female gender .05
Age 70 years .10
Bilateral disease .14
Abdominal aortic aneurysm .16
Diabetes mellitus .20
Severe diastolic hypertension, 180 mm Hg .23
Gold stent type .25
Severe systolic hypertension, 90 mm Hg .32
Embolic protection .65
Coronary artery disease .71
Chronic obstructive pulmonary disease .78
Hypercholesterolemia .99
Smoking .99
eGFR, Estimated glomerular filtration rate.eGFR at the last follow-up across the patient population
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16%, stable in 60%, and worse in 24% of patients (Fig 4).
DISCUSSION
RAS has become a widespread therapeutic intervention
for patients with renal artery stenosis in the setting of
hypertension. Unfortunately, despite high technical success
and low complication rates,6,7 the clinical response has
been less impressive. Early improvement in blood pressure
response is evident in about 60% to 70% of patients, but
long-term data are variable and generally lacking.15,16
Poor patient selection may account for lackluster dura-
bility, and determining predictors for successful therapy is
paramount to improving the overall success of the proce-
dure. Previous reports have determined factors associated
with poor outcomes after RAS, including pre-existing se-
vere renal parenchymal disease,8 pre-existing high creati-
Fig 2. Blood pressure improvement or cure after renal artery
stenting is shown stratified by baseline estimated glomerular filtra-
tion rate (eGFR) of 40 or 40 mL/min/1.73 m2. The differ-
ence between the patient groups at 24 to 48 months of follow-up
is significant (P  .02).
Fig 3. Survival after renal artery stent placement is shown accord-
ing to blood pressure response of improvement or cure (blue line)
or unchanged or worse (red line).nine level,9 higher mean blood pressure value,9 type ofstent,17 brain natriuretic peptide level, and fractional flow
reserve in the kidney.10,11
Some of these predictors remain controversial, and
subsequent publications have demonstrated conflicting re-
sults. For example, a high renal parenchymal resistive index,
as reported by Radermacher et al in the New England
Journal of Medicine in 2001,8 is predictive of a poor re-
sponse to renal angioplasty. Zeller and others9,18 subse-
quently have called this into question and demonstrated a
favorable response to stenting, even in individuals with
pre-existing nephrosclerosis.
Determining outcomes with regard to renal function
after stenting was not a primary end point of this study;
however, it appears that stenting did not improve renal
function in any of the patients. Nephrosclerosis is a com-
plex disease process with many potentially overlapping
etiologies in patients with peripheral vascular disease. Pa-
tients with purely ischemic nephropathy will likely respond
differently to therapy than patients with hypertensive ne-
phropathy, diabetic nephropathy, or some combination of
these or other conditions. It may be important to distin-
guish among these patients to determine optimal treat-
ment. This is reflected in the heterogeneous outcomes seen
in our patients with pre-existing nephrosclerosis as well as
those reported in previous studies.8,9
Our data suggest that patient selection is crucial. Those
patients with normal preprocedural renal function clearly
respond to therapy more favorably. Some patients with
pre-existing renal insufficiency do respond to therapy, how-
ever: 31% of these patients derived a continued benefit at 2
to 4 years of follow-up. Female gender was also an inde-
pendent predictor of therapeutic failure, which was inde-
pendent of renal artery diameter. In contrast to our finding,
Harjai et al19 reported no gender difference in response to
renal stent placement for RVH in their series of 66 patients.
However, their early and late results both showed trends
toward better blood pressure outcomes in men. Al-
though these two factors indicate a potential for thera-
peutic failure, they should not exclude patients from
treatment, because there are patients with these character-
Fig 4. Response of estimated glomerular filtration rate after renal
artery stenting is shown in patients at the last follow-up.istics who receive lasting benefit from RAS.
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possible for us to stratify the response to therapy to deter-
mine what level of cardiovascular benefit these patients are
receiving in the long-term.Many patients have only modest
improvement in their blood pressure or a small decrease in
their antihypertensive regimen. It is impossible to know
from these data how much these decreases over a relatively
brief time interval improve their overall health state or
mitigate any existing cardiovascular disease. Our analysis
found no improvement in midterm survival of patients after
RAS based on whether they had a blood pressure response
to treatment.
However, data in the existing literature demonstrate
detrimental effects of even mild hypertension and demon-
strable cardiovascular benefits with treatment. In a meta-
analysis of 61 observational studies including 1 million
patients, Lewington et al20 demonstrated a linear increase
in death from ischemic heart disease and stroke from blood
pressure values as low as 115 mm Hg SBP and 75 mm Hg
DBP. An increase of 20 mm Hg systolic or 10 mm Hg
diastolic correlated to a doubling of the lifetime risk of
death from ischemic heart disease and stroke. Multiple
randomized trials have also demonstrated clinical benefit to
blood pressure treatment using varying forms of medica-
tions in various combinations.21 Whether these same clin-
ical benefits are achieved with successful treatment of RVH
remains to be demonstrated.
Limitations to this study include the relatively small
patient sample and the single-institution practice, which
inherently adds selection bias. Also, blood pressure data
included in this study were measured at a single clinic visit
and may not reflect the average blood pressure of the
patient over time. In addition, other factors may have some
effect on outcome such as the use of embolic protection
devices as well as performing staged stenting of bilateral
renal arteries, which were inconsistently applied across our
patient sample.
CONCLUSIONS
The long-term outcomes of RAS are mixed. Patients
treated for RVHwith a normal baseline renal function have
a significant and relatively durable response to RAS. How-
ever, these data demonstrate sobering long-term results
from RAS in patients with poor renal function before the
procedure. No firm clinical recommendations can be made
based on the results of this study due to the noted limita-
tions. These data, however, do provide guidelines for dis-
cussions with patients about the expected outcome of the
procedure. Further studies using randomized controlled
trials, such as the forthcoming CORAL (Cardiovascular
Outcomes in Renal Atherosclerotic Lesions) trial to delin-
eate which patients will respond to therapy, are certainly
warranted.
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Dr Matthew Edwards (Winston-Salem, NC). Good morn-
ing. I would like to thank the Society and the program committee
for the opportunity to discuss this presentation on the topic of
predicting long-term blood pressure responses following renal
artery stenting. I would also like to congratulate Dr Beck on his
presentation.
Treatment of renovascular disease is a highly controversial
topic in 2009. Eighteen months ago, Drs Richard Cambria, Rob-
ert Zwolak, and I performed variable roles at a meeting of the CMS
[Centers for Medicare and Medicaid Services] Medical Evidence
Development and Coverage Advisory Committee regarding reno-
vascular disease treatment. At that meeting it was very clear that
renal artery stenting has come under the microscope of scrutiny by
the nation’s largest third payor. The principle topic of discussion
was the lack of any meaningful controlled data demonstrating
efficacy of stenting in improving outcomes and, more specifically,
outcomes of reducing subsequent cardiovascular disease events,
preventing dialysis dependence, and improving survival free of
these problems. A prolonged discussion of the most appropriate
means of procuring such data was discussed, and several proposals
of limiting reimbursement for stenting, similar to those currently
employed for carotid artery stenting, were voted upon. Ultimately,
the decision was made by the group to recommend continued
funding of renal stenting until data from currently enrolling trials
such as CORAL [Cardiovascular Outcomes in Renal Atheroscle-
rotic Lesions] were completed. Given the heightened scrutiny,
reimbursement policies will almost certainly be revisited at that
time.
Two of the issues prompting that meeting were (1) known
variability of early results following renal artery stenting and (2) the
lack of durability of those results. In this presentation Dr Beck
describes 129 patients treated, with only 16% experiencing im-
proved renal function, 24% having worsened renal function, and
45% to 55% having improved hypertension, with 40% of these
having subsequent deterioration of their hypertension response.
Moderate to severe chronic kidney disease in female gender were
identified as significant and independent predictors of deteriorat-
ing response. I have several questions for Dr Beck.
First, I would like some clarification on the issue of restenosis.
Your group reports a very high rate of restenosis approximating
50% at 18 months. Only 27% of these patients received repeat
intervention. What clinical manifestations did you observe in these
patients and how did you approach their treatment? While I
understand that you are looking for identifiable preoperative risk
factors for poor hypertension response to guide future patient
selection, I think that you must consider or adjust for this known,
time-dependent cause of recurrent hypertension in your analyses
or risk type I error by not considering its potential confounding
effects.
Second, and more importantly, with only 30% to 40% of
patients achieving durable hypertension response, 24% experienc-
ing short-term renal function deterioration, and a 50% rate of
stenosis at 18 months, do you think you are helping or hurting the
majority of patients treated? Also, how will these data impact yourFinally, in your analyses you report that blood pressure re-
sponses did not impact survival, but renal function responses did
impact survival. Don’t you think that looking at predictors of renal
function response might be more important than looking at pre-
dictors of blood pressure response? Again I ask the question, does
this affect your selection criteria for stenting going forward?
I look forward to your answers and thank you again for the
privilege of the floor.
Dr AdamW. Beck. Regarding the restenosis data, I am sorry
I wasn’t here for the presentation, but I saw the abstract that Dr
Corriere presented yesterday, and regarding restenosis there, I
think that yourmedian follow-up was about 5½months, and if you
look at our restenosis rate on a Kaplan-Meier curve, our restenosis
is 50% at 18months, which obviously is a significantly high number
of those patients, and that is based on duplex criteria alone and so
we have selectively reintervene on those patients if they have a
progressive stenosis on duplex, they may get intervention. Obvi-
ously, whether they have had a response to the therapy in the first
place, it is going to impact whether we reintervene or not.
If they have clinical manifestations of their progressive stenosis
or any stenosis on duplex, then we would intervene. So if they
come in with what appears to be renovascular hypertension or
recurrent hypertension, we would then intervene. If they have a
60% restenosis and they are clinically doing well, their hypertension
is controlled, there is not evidence of renal dysfunction, then we
would not reintervene unless they had, again, progressive stenosis
on ultrasound. So those patients, the 27% that are reported in the
paper and not in this presentation, underwent reintervention for
recurrent clinical evidence of stenosis.
Regarding whether we are helping or hurting the patients, I
think that is an excellent question and I think that is the ultimate
question of renal stenting. In terms of the deterioration of renal
function that I presented, all of these patients underwent interven-
tion for renovascular hypertension, not for renal insufficiency, so
the primary goal of their therapy was to treat the renovascular
hypertension, and so whether the renal function improved or not
was not a primary outcome measure, and I think that is probably
more of an indication of the progression of their disease and it may
just be the natural history of their disease, we just don’t know.
I think that the data out there for treating patients for renal
insufficiency with renal stents are definitely very soft, even more
soft than renovascular hypertension, so at this time, we generally
just treat for renovascular hypertension if they happen to have renal
insufficiency, then that is just part of it. Whether I think we may be
hurting some patients, and I think some of the work that you are
doing with embolic protection devices is probably going to end up
being very important, especially in patients that have chronic renal
insufficiency along with renovascular hypertension.
The third question that you are asking about looking at
predictors for renal function response, I think that is a very good
question, and again, our secondary goal of the renal stenting was to
treat the renal insufficiency and so we primarily wanted to look at
predictors of outcome for our primary treatment goal.
